Registration for a live webinar on 'Phasing Out Animal Testing: A New Era for Pharmaceutical Innovation' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Research interviews
-
21 min
1. The role of preregistration and registered reports in improving research transparency and reproducibility- Dr. Peter Bonde Ernst-Rasmussen
-
17 min
2. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD- Prof. Katrin Andreasson
-
3. The safety, toxicology, and regulation of antibody-drug conjugates- Dr. Veysel Kayser
-
13 min
4. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
18 min
-
18 min
6. Cancer vaccines- Dr. Elias Sayour
-
13 min
7. The regulation of cell therapy- Prof. Moutih Rafei
-
17 min
8. How and why neurons die in Alzheimer's disease?- Prof. Bart De Strooper
-
11 min
9. The future of blood tests in cancer treatment- Dr. Isaac Garcia-Murillas
-
50 min
10. Role of marketing authorization holder in drug safety- Dr. Raphael Elmadjian Pareschi
-
25 min
11. Synthetic whole embryo models and their applications- Prof. Jacob (Yaqub) Hanna
-
31 min
12. Scale-up challenges in the production of nanomedicines from lab to industry- Prof. Dr. Oya Tagit
-
14 min
13. Artificial intelligence in precision medicine- Dr. Michael P. Menden
-
30 min
14. Translational medicine: the risk of failure in delay and how to reduce it- Prof. Martin Wehling
-
8 min
15. Challenges and solutions of scaling up- Dr. Shaukat Ali
-
15 min
-
31 min
17. Management of generic drug development: challenges and opportunities- Mr. Sandeep Patil
-
10 min
18. MassBank development and future- Dr. Emma L. Schymanski
-
31 min
19. Elite controllers of HIV: from discovery to future therapies- Prof. Bruce Walker
-
25 min
20. Translational research in amyotrophic lateral sclerosis (ALS)- Prof. Aaron D. Gitler
-
29 min
21. Rheumatic diseases and musculoskeletal pain- Prof. Anisur Rahman
-
23 min
22. Towards developing a universal influenza vaccine- Prof. Peter Palese
- Clinical interviews
-
25 min
23. PANDAS: a potential link between group A streptococcal infections and neurological disorders- Prof. P. Patrick Cleary
-
10 min
-
17 min
25. Artificial intelligence in guiding cancer treatment decisions- Prof. Eytan Ruppin
-
6 min
26. Characterizing barriers to care in migraine- Prof. Dawn C. Buse
-
21 min
27. Monkeypox: etiopathogenesis, prevention, and treatments- Dr. Dennis Hruby
-
7 min
-
13 min
29. Kidney xenotransplantation- Dr. Douglas J. Anderson
-
28 min
30. CAR-T and TCR-T cellular immunotherapies in oncology- Prof. Sebastian Kobold
-
28 min
31. MAPS: the business of medical affairs- Dr. Danie du Plessis
-
26 min
32. Hypertrophic cardiomyopathy: therapies and treatments- Prof. Srihari Naidu
-
24 min
33. Combating the HIV epidemic- Prof. William Blattner
-
17 min
34. Epigenetic pharmaceuticals used in the clinic- Dr. Thomas Paul
-
21 min
35. Precision cancer medicine: development and future- Prof. Maurie Markman
-
31 min
36. Pediatric cancer testing- Prof. Joshua Schiffman
-
27 min
37. Opposition to vaccination: a transatlantic discussion- Prof. Jonathan Temte
-
26 min
38. Elective caesarean sections from an evolutionary perspective- Prof. Wenda Trevathan
-
19 min
39. Antiphospholipid syndrome and Lupus- Prof. Graham Hughes
-
16 min
40. Prescribing medications to children - a GP’s view- Dr. Amanda Simmons
Topics Covered
- Alzheimer Disease (AD)
- Blood biomarkers
- Primary care and secondary care
- APS2
- p-tau217
Biography
Dr. Gemma Salvadó is an associate researcher at Lund University in Sweden with a background in physics and biomedical engineering. She completed her PhD at the Barcelonaßeta Brain Research Center in Spain, where she studied the preclinical stages of Alzheimer's disease using neuroimaging and fluid biomarkers. Her current research focuses on plasma and cerebrospinal fluid biomarkers to understand disease progression. Dr. Salvadó has authored 44 peer-reviewed articles, including 14 as the first author, many published in high-impact journals. Her work has received significant recognition, with a notable increase in citations. She was awarded the prestigious Marie Sklodowska-Curie post-doctoral fellowship, along with other significant fellowships such as the Alzheimer's Association Research Fellowship and the Alzheimerfonden Fellowship. She has presented her research at esteemed conferences, earning the Junior Faculty Award at the AD/PD conference. Dr. Salvadó has contributed to two large European-funded projects, EPAD and AMYPAD, focused on Alzheimer's disease research. She also serves as a reviewer for esteemed journals and participates in reviewing grants and awards. Additionally, Dr. Salvadó has been a member of the Executive Committee of the Neuroimaging Professional Interest Area of the Alzheimer's Association. Her extensive contributions highlight her dedication and impact on Alzheimer's disease research.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Salvadó, G. (2025, February 27). Blood biomarkers: a new frontier in early Alzheimer’s detection in primary and secondary care [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 3, 2025, from https://doi.org/10.69645/LTJW9085.Export Citation (RIS)
Publication History
- Published on February 27, 2025
Financial Disclosures
- Dr. Gemma Salvadó has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
Blood biomarkers: a new frontier in early Alzheimer’s detection in primary and secondary care
Published on February 27, 2025
7 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
Hide